Premium
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy
Author(s) -
Li Hongjin,
Sereika Susan M.,
Marsland Anna L.,
Conley Yvette P.,
Bender Catherine M.
Publication year - 2019
Publication title -
journal of clinical nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.94
H-Index - 102
eISSN - 1365-2702
pISSN - 0962-1067
DOI - 10.1111/jocn.15047
Subject(s) - aromatase inhibitor , aromatase , medicine , breast cancer , chemotherapy , oncology , postmenopausal women , cancer , gynecology
Aims and Objectives To examine and compare the differences in symptoms and symptom clusters between postmenopausal women with early‐stage breast cancer who did and did not receive chemotherapy prior to aromatase inhibitor (AI) therapy. Background Women with breast cancer often experience multiple concurrent symptoms during AI therapy. The burden of symptoms prior to AI is associated with nonadherence to cancer treatment. To date, few studies have comprehensively explored the symptoms and symptom clusters occurring prior to AI therapy. Design Secondary analysis of a prospective repeated‐measures study. Methods The sample comprised postmenopausal women ( N = 339) with breast cancer who would receive AI therapy with or without chemotherapy. We collected information on 48 symptoms after surgery or chemotherapy but before AI therapy using different symptom assessment tools. Mann–Whitney U tests were used to compare the differences in the severity of symptoms between groups. Exploratory factor analysis (EFA) was conducted to determine symptom clusters. This study followed STROBE guidelines. Results The most severe symptoms among women with breast cancer prior to AI therapy were breast sensitivity, unhappy with the appearance of my body, general aches and pain, joint pain and muscle stiffness. Women who received chemotherapy prior to AI therapy experienced significantly higher severity of 22 symptoms than women who did not receive chemotherapy. Through EFA seven distinct symptom clusters were revealed in both groups: cognitive, musculoskeletal, psychological, vasomotor, weight, sexual and urinary, with additional gastrointestinal symptom cluster been identified in women who received chemotherapy. Conclusions This study indicates the presence of symptoms among women with breast cancer prior to AI therapy, with higher severity of symptoms and greater number of symptom clusters for women who received chemotherapy. Relevance to clinical practice Nurses should assess and be aware of symptoms and symptom clusters existed prior to AI therapy and manage them in advance.